The FN rate is defined as the number of participants who experience treatment-emergent FN.

For Part A, the full analysis set included all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

CR rate at EOT is defined as the percentage of participants with CR at EOT, according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Cheson 2016), in participants with previously untreated cHL.

For Parts B and C, the full analysis set included all participants who enrolled and received any amount of the combination therapy in the study.

An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with the treatment. Participants with peripheral neuropathy (PN) adverse events were summarized under AECI.

For Part A, the full analysis set included all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

The primary refractory disease rate is defined as the percentage of participants with less than complete response or relapse within 3 months of EOT, according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

The complete response rate is defined as the percentage of participants with CR at EOT according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

The physician-reported PFS rate at 2 years is estimated based on Kaplan-Meier methodology. The determination of antitumor activity will be based on response assessments made according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

Number of participants with subsequent anticancer therapy have been reported in this outcome measure.

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

For Part A, the full analysis set includes all participants who received at least 1 dose of A+AVD (any of the study drugs in the regimen).

For Parts B and C, the full analysis set includes all participants who enrolled and received any amount of the combination therapy in the study.

Laboratory values were graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). As per NCI CTCAE version 4.03 grading, Grade 1 indicated mild or asymptomatic laboratory abnormalities, Grade 2 indicated moderate laboratory abnormalities, and Grade 3 indicated severe and 4 indicated life-threatening laboratory abnormalities.

For Parts B and C, the full analysis set included all participants who enrolled and received any amount of the combination therapy in the study.

ORR is defined as the percentage of participants with CR or partial response (PR) at EOT according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) in participants with previously untreated cHL.

For Parts B and C, the full analysis set included all participants who were enrolled and received any amount of the combination therapy in the study.

DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. Duration of response was only calculated for the subgroup of participants achieving a CR or PR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.

For Parts B and C, the full analysis set includes all participants who were enrolled and received any amount of the combination therapy in the study. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

DOCR was defined as the time from start of the first documentation of CR to the first documentation of tumor progression (per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. DOCR was calculated for the subgroup of participants achieving CR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.

For Parts B and C, the full analysis set includes all participants who were enrolled and received any amount of the combination therapy in the study. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure.

EFS was defined as the time from the start of study treatment to the first documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive disease, whichever occurred first. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. EFS rate was percentage of participants with EFS.

For Parts B and C, the full analysis set includes all participants who were enrolled and received any amount of the combination therapy in the study.

PFS was defined as the time from start of study treatment to first documentation of objective tumor progression or death. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.

For Parts B and C, the full analysis set includes all participants who were enrolled and received any amount of the combination therapy in the study.

OS was defined as the time from start of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. Kaplan-Meier method was used.

For Parts B and C, the full analysis set includes all participants who were enrolled and received any amount of the combination therapy in the study.